Faster drug launches and market access, along with a well-planned price-reimbursement strategy, can offer several benefits for pharmaceutical companies.
Addressing Unmet Medical Needs
Market Share Expansion
Pricing and Reimbursement Optimization
The growing number of FDA NDA & BLA approvals for New Molecular Entities (NMEs) is an encouraging trend in the pharmaceutical industry. However, with increased approvals comes heightened competition. The expanding market for NMEs means that pharmaceutical companies must navigate a highly competitive landscape to differentiate their products and gain market share. It requires diligent efforts in research, development, and commercialization strategies to stand out from the crowd.
What are Price and Market Access Services?
How are these services tailored to individual businesses?
Can these services help with international market access?
Are these services only relevant for new products or businesses?
How can I get started with Price and Market Access Services for my business?
Can I integrate these services API with my existing portal?
What type of services you provide in Pricing and Market access?
In which regions you provide these services?
What type of information covered in the excel report?
Report is at SKU level or at product level?
How will this report help to understand launch sequence?
Historical prices are available from which year?
What are different price levels are covered?
Are you providing subsequent updates and how?